Yolanda Almaden
Overview
Explore the profile of Yolanda Almaden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
1161
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Diaz-Tocados J, Rodriguez-Ortiz M, Herencia C, Lopez-Baltanas R, Jurado-Montoya D, Garcia-Saez R, et al.
FASEB J
. 2024 Jun;
38(11):e23726.
PMID: 38847773
Calcitriol and calcimimetics are used to treat hyperparathyroidism secondary to chronic kidney disease (CKD). Calcitriol administration and the subsequent increase in serum calcium concentration decrease parathyroid hormone (PTH) levels, which...
2.
Bover J, Trinidad P, Jara A, Soler-Majoral J, Martin-Malo A, Torres A, et al.
Nefrologia (Engl Ed)
. 2023 Mar;
42(6):645-655.
PMID: 36925324
Although phosphorus is an essential element for life, it is not found in nature in its native state but rather combined in the form of inorganic phosphates (PO), with tightly...
3.
Lopez-Baltanas R, Rodriguez-Ortiz M, Diaz-Tocados J, Martinez-Moreno J, Membrives C, Rodelo-Haad C, et al.
Antioxidants (Basel)
. 2023 Feb;
12(2).
PMID: 36829843
Background: Metabolic syndrome (MetS) and chronic kidney disease (CKD) are commonly associated with cardiovascular disease (CVD) and in these patients Mg concentration is usually decreased. This study evaluated whether a...
4.
Bover J, Arana C, Urena P, Torres A, Martin-Malo A, Fayos L, et al.
Nefrologia (Engl Ed)
. 2022 Sep;
41(5):514-528.
PMID: 36165134
Secondary hyperparathyroidism (SHPT) is an integral component of the chronic kidney disease-mineral and bone disorder (CKD-MBD). Many factors have been associated with the development and progression of SHPT but the...
5.
Vergara N, Pendon-Ruiz de Mier M, Rodelo-Haad C, Revilla-Gonzalez G, Membrives C, Diaz-Tocados J, et al.
Nephrol Dial Transplant
. 2022 Jul;
38(2):322-343.
PMID: 35867864
Background: In chronic kidney disease (CKD) patients, increased levels of fibroblast growth factor 23 (FGF23) are associated with cardiovascular mortality. The relationship between FGF23 and heart hypertrophy has been documented,...
6.
Lopez-Baltanas R, Rodriguez-Ortiz M, Canalejo A, Diaz-Tocados J, Herencia C, Leiva-Cepas F, et al.
Eur J Clin Invest
. 2021 Apr;
51(8):e13561.
PMID: 33870500
Background: Inflammation is a common feature in chronic kidney disease (CKD) that appears specifically associated with cardiovascular derangements in CKD patients. Observational studies have revealed a link between low Mg...
7.
Rodriguez-Ortiz M, Alcala-Diaz J, Canalejo A, Torres-Pena J, Gomez-Delgado F, Munoz-Castaneda J, et al.
Eur J Intern Med
. 2020 Jan;
74:79-85.
PMID: 31899053
Background: Fibroblast growth factor 23 (FGF23) is a major determinant of mineral metabolism derangements and emerges as a possible risk factor underlying the negative cardiovascular outcome in CKD patients. However,...
8.
Rodriguez-Ortiz M, Diaz-Tocados J, Munoz-Castaneda J, Herencia C, Pineda C, Martinez-Moreno J, et al.
Clin Sci (Lond)
. 2019 Dec;
134(1):15-32.
PMID: 31860056
Fibroblast growth factor 23 (FGF23) increases phosphorus excretion and decreases calcitriol (1,25(OH)2D) levels. FGF23 increases from early stages of renal failure. We evaluated whether strict control of phosphorus intake in...
9.
Rodriguez-Ortiz M, Gomez-Delgado F, Arenas de Larriva A, Canalejo A, Gomez-Luna P, Herencia C, et al.
Sci Rep
. 2019 May;
9(1):8013.
PMID: 31142774
This study aimed to ascertain whether there is an independent association between serum magnesium (Mg) and the Carotid Intima-Media Thickness (IMT-CC), a well-accepted atherosclerotic-biomarker surrogate of cardiovascular disease (CVD), in...
10.
Diaz-Tocados J, Rodriguez-Ortiz M, Almaden Y, Pineda C, Martinez-Moreno J, Herencia C, et al.
Kidney Int
. 2019 Mar;
95(5):1064-1078.
PMID: 30878213
Calcimimetics decrease parathyroid hormone (PTH) secretion in patients with secondary hyperparathyroidism. The decrease in PTH should cause a reduction in bone turnover; however, the direct effect of calcimimetics on bone...